LLY receives FDA approval for Inluriyo.
Eli Lilly and Company（LLY）的 Inluriyo 获美国 FDA 批准。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
Guggenheim raises LLY target to $1,284Guggenheim 上调目标价 礼来 (LLY) 至 $1,284
Rating Change · September 18, 2026评级变动 · 2026/9/18
HSBC raises LLY target to $940 from $850HSBC 上调目标价 礼来 (LLY)：$850 → $940
Rating Change · September 10, 2026评级变动 · 2026/9/10
LLY regulatory decision: FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetesEli Lilly and Company（LLY）的 产品 获美国 FDA 许可或批准
Material Company Event · August 28, 2026公司公告 · 2026/8/28
